Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Olmesartan (RNH 6270) 是一种血管紧张素 II 受体 (AT1R) 拮抗剂,常用于研究高血压。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 258 | 现货 | ||
25 mg | ¥ 413 | 现货 | ||
50 mg | ¥ 663 | 现货 | ||
100 mg | ¥ 1,080 | 现货 | ||
500 mg | ¥ 2,680 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | Olmesartan (RNH 6270) is an Angiotensin II Type I receptor antagonist. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil,and has antihypertensive activity. |
体内活性 | The target blood pressure (<130/80 mm Hg) was achieved in nearly 80% of the patients taking olmesartan and 71% taking placebo;?blood pressure measured in the clinic was lower by 3.1/1.9 mm Hg in the olmesartan group than in the placebo group.?Microalbuminuria developed in 8.2% of the patients in the olmesartan group (178 of 2160 patients who could be evaluated) and 9.8% in the placebo group (210 of 2139);?the time to the onset of microalbuminuria was increased by 23% with olmesartan (hazard ratio for onset of microalbuminuria, 0.77;?95% confidence interval, 0.63 to 0.94;?P=0.01).?The serum creatinine level doubled in 1% of the patients in each group.?Slightly fewer patients in the olmesartan group than in the placebo group had nonfatal cardiovascular events--81 of 2232 patients (3.6%) as compared with 91 of 2215 patients (4.1%) (P=0.37)--but a greater number had fatal cardiovascular events--15 patients (0.7%) as compared with 3 patients (0.1%) (P=0.01),?a difference that was attributable in part to a higher rate of death from cardiovascular causes in the olmesartan group than in the placebo group among patients with preexisting coronary heart disease (11 of 564 patients [2.0%] vs. 1 of 540 [0.2%], P=0.02)[1]. |
动物实验 | In a randomized, double-blind, multicenter, controlled trial, Assigned 4447 patients with type 2 diabetes to receive olmesartan (at a dose of 40 mg once daily) or placebo for a median of 3.2 years.?Additional antihypertensive drugs (except angiotensin-converting-enzyme inhibitors or ARBs) were used as needed to lower blood pressure to less than 130/80 mm Hg. The primary outcome was the time to the first onset of microalbuminuria.?The times to the onset of renal and cardiovascular events were analyzed as secondary end points[1]. |
别名 | CS 088, 奥美沙坦, RNH 6270 |
分子量 | 446.5 |
分子式 | C24H26N6O3 |
CAS No. | 144689-24-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (123.18 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2396 mL | 11.1982 mL | 22.3964 mL | 55.991 mL |
5 mM | 0.4479 mL | 2.2396 mL | 4.4793 mL | 11.1982 mL | |
10 mM | 0.224 mL | 1.1198 mL | 2.2396 mL | 5.5991 mL | |
20 mM | 0.112 mL | 0.5599 mL | 1.1198 mL | 2.7996 mL | |
50 mM | 0.0448 mL | 0.224 mL | 0.4479 mL | 1.1198 mL | |
100 mM | 0.0224 mL | 0.112 mL | 0.224 mL | 0.5599 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Olmesartan 144689-24-7 Endocrinology/Hormones RAAS CS 088 Inhibitor Angiotensin Receptor RNH6270 奥美沙坦 CS-088 CS088 RNH-6270 RNH 6270 inhibit inhibitor